{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:31:35Z","timestamp":1788370295344,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023554","name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Using machine learning to identify clinical biomarkers for determining optimal response to mepolizumab in chronic rhinosinusitis with nasal polyps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single center retrospective observational study with 84 CRSwNP patients treated with mepolizumab. We evaluated 4 machine learning algorithms: Decision Tree, Logistic Regression, K-Nearest Neighbors and Extreme Gradient Boosting. K-Fold cross-validation incorporating hyperparameter optimization in the process was used to ensure robustness and prevent overfitting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 6, 12 and 24 months, SNOT-22, VAS overall symptom score, VAS-smell, asthma control test (ACT) and nasal polyp score (NPS) significantly improved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). 44.1% of patients were classified as \u201csuper-responders\u201d after 2-year of Mepolizumab treatment based on EPOS\/Euforea criteria. XGBoost emerged as the most accurate for predicting super-response to mepolizumab, achieving an ROC- AUC of 0.766. In contrast, Logistic Regression was the least effective for predicting sustained super-response at 24 months, with an ROC-AUC of 0.628. Significant predictors included Blood Neutrophilia and Blood Eosinophilia where higher baseline scores were linked to higher probabilities of super-response at 24 months. Shapley Additive Explanations were employed to identify the most critical baseline features and to visualize their directional impacts on treatment responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Machine learning models, particularly XGBoost, can predict real-world super-response to mepolizumab in severe CRSwNP by identifying key predictors like high baseline BEC, high baseline BNC and AERD comorbidity. These insights have the potential to refine CRSwNP treatment strategies and support clinical decision-making, ultimately enhancing patient outcomes by predicting treatment response prior to starting medication<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1710163","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:40:00Z","timestamp":1770964800000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Using machine learning to define mepolizumab treatment response at 2 years in patients with chronic rhinosinusitis with nasal polyps"],"prefix":"10.3389","volume":"7","author":[{"given":"Mar\u00eda Sandra","family":"Dom\u00ednguez-Sosa","sequence":"first","affiliation":[{"name":"Hospital Universitario de Gran Canaria Dr Negrin","place":["Las Palmas de Gran Canaria, Spain"]},{"name":"Universidad de Las Palmas de Gran Canaria","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Soledad","family":"Cabrera-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Dr Negrin","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam del Carmen","family":"Marrero-Ramos","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Dr Negrin","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cabrera-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Dr Negrin","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Carrillo-D\u00edaz","sequence":"additional","affiliation":[{"name":"Universidad de Las Palmas de Gran Canaria","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Ben\u00edtez-Rosario","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Gran Canaria Dr Negrin","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Delia","family":"D\u00e1vila-Quintana","sequence":"additional","affiliation":[{"name":"Universidad de Las Palmas de Gran Canaria","place":["Las Palmas de Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JAA.S86251","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J Asthma Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2500\/ajra.2014.28.4076","article-title":"A comparative and descriptive study of asthma in chronic rhinosinusitis with nasal polyps","volume":"28","author":"H\u00e5kansson","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/nejmra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez","year":"2023","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1016\/j.jaip.2024.09.021","article-title":"Efficacy of biologics in NSAID-ERD: united airways from the nose to the bronchi","volume":"12","author":"Buchheit","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/jpm12081304","article-title":"Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study","volume":"12","author":"Gallo","year":"2022","journal-title":"J Pers Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4193\/Rhin25.121","article-title":"One-year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study","volume":"63","author":"De Corso","year":"2025","journal-title":"Rhinology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1714577","DOI":"10.3389\/falgy.2025.1714577","article-title":"Chronic rhinosinusitis with and without nasal polyps: the state-of-the-art of current treatment strategies and future developments","volume":"6","author":"Nappi","year":"2025","journal-title":"Front. Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1016\/s2213-2198(23)00970-4","article-title":"Artificial intelligence\u2019s potential in tailoring prescription of biologic therapy for chronic rhinosinusitis","volume":"11","author":"Minzoni","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2017.18391.4","article-title":"Big data and machine learning in health care","volume":"319","author":"Beam","year":"2018","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From local explanations to global understanding with explainable AI for trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat Mach Intell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12874-022-01577-x","article-title":"Methodological conduct of prognostic prediction models developed using machine learning in oncology: a systematic review","volume":"22","author":"Dhiman","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/all.15168","article-title":"Predicting the recurrence of chronic rhinosinusitis with nasal polyps using nasal Microbiota","volume":"77","author":"Zhao","year":"2021","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"108031","DOI":"10.1016\/j.envint.2023.10803","article-title":"Individual exposure of ambient particulate matters and eosinophilic chronic rhinosinusitis with nasal polyps: dose-response, mediation effects and recurrence prediction","volume":"177","author":"Wang","year":"2023","journal-title":"Environ Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26355\/eurrev_202501_37054","article-title":"Prediction of phenotypes by secretory biomarkers and machine learning in patients with chronic rhinosinusitis","volume":"29","author":"Becker","year":"2025","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1054201","DOI":"10.3389\/fimmu.2022.1054201","article-title":"A diagnostic model for predicting type 2 nasal polyps using biomarkers in nasal secretion","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/alr.22632","article-title":"Machine learning of biomarkers and clinical observation to predict eosinophilic chronic rhinosinusitis: a pilot study","volume":"11","author":"Thorwarth","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205pp","article-title":"Global initiative for asthma strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence","volume":"145","author":"Bousquet","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2013","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","article-title":"European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis","volume":"78","author":"Gevaert","year":"2023","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1398-9995.2011.02728.x","article-title":"Practical guide to skin prick tests in allergy to aeroallergens","volume":"67","author":"Bousquet","year":"2012","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0194-59989770005-6","article-title":"Staging for rinosinusitis","volume":"117","author":"Lund","year":"1997","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1513\/AnnalsATS.202106-653OC","article-title":"Novel methods of measuring adherence patterns reveal adherence phenotypes with distinct asthma outcomes","volume":"19","author":"Huvanandana","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the asthma control test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14639\/0392-100X-N0364","article-title":"Prognostic value of the sinonasal outcome test 22 (SNOT-22) in chronic rinosinusitis","volume":"40","author":"Gallo","year":"2020","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"B32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1214\/aos\/1013203451","article-title":"Greedy function approximation: a gradient boosting machine","volume":"29","author":"Friedman","year":"2001","journal-title":"Ann Stat"},{"key":"B35","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4193\/rhin24.337","article-title":"Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma","author":"Mullol","year":"2024","journal-title":"Rhinology Journal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/jcm13123575","article-title":"Real-life evidence of mepolizumab treatment in chronic rhinosinusitis with nasal polyps: a multicentric study","volume":"13","author":"Cavaliere","year":"2024","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00405-024-09027-8","article-title":"Effects of mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study","volume":"282","author":"Orlando","year":"2024","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.3390\/jcm14155248","article-title":"Transforming patient experience: real-world impact of mepolizumab on symptom burden in chronic rhinosinusitis with nasal polyps\u2014a multicenter perspective","volume":"14","author":"Garc\u00eda","year":"2025","journal-title":"J Clin Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.amjoto.2024.104329","article-title":"Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: real life data in a tertiary care","volume":"45","author":"Galletti","year":"2024","journal-title":"Am J Otolaryngol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.amjoto.2024.104597","article-title":"Mepolizumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric sicilian experience","volume":"46","author":"Galletti","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.jaip.2023.05.011","article-title":"The unified airway hypothesis: evidence from specific intervention with anti-IL-5 biologic therapy","volume":"11","author":"Bachert","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"PA448","DOI":"10.1183\/13993003.congress-2024.pa448","article-title":"Predicting real-world response to mepolizumab in severe asthma using machine learning","volume":"64","author":"Usuba","year":"2024","journal-title":"Epidemiology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.iac.2016.06.004","article-title":"Aspirin-exacerbated respiratory disease as an endotype of chronic rhinosinusitis","volume":"36","author":"Stevens","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/alr.23283","article-title":"Histopathologic features of biologic therapy nonresponders in chronic rhinosinusitis with nasal polyposis","volume":"14","author":"Baird","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/biomedicines11092424","article-title":"Long-term efficacy of mepolizumab at 3 years in patients with severe asthma: comparison with clinical trials and super responders","volume":"11","author":"Bagnasco","year":"2023","journal-title":"Biomedicines"},{"key":"B50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/02770903.2022.2036754","article-title":"Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience","volume":"60","author":"Matucci","year":"2022","journal-title":"J Asthma"},{"key":"B51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/rhin22.416","article-title":"Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: sYNAPSE","volume":"62","author":"Mullol","year":"2024","journal-title":"PubMed"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.3390\/ijms26104694","article-title":"Long-Term real-world outcomes and insights of biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"26","author":"Book","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/alr.23282","article-title":"Predictors of persistent disease in biologic treated type 2 diffuse\/eosinophilic chronic rhinosinusitis undergoing surgery","volume":"14","author":"Png","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/pharmaceutics16111370","article-title":"Investigation of blood count-based inflammatory biomarkers as predictors of response to dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps","volume":"16","author":"Habenbacher","year":"2024","journal-title":"Pharmaceutics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40463-023-00660-7","article-title":"Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis","volume":"52","author":"Brkic","year":"2023","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","article-title":"Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps","volume":"155","author":"Kratchmarov","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"105806","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11882-023-01114-w","article-title":"Type 2 biomarkers for the indication and response to biologics in CRSwNP","volume":"23","author":"Guo","year":"2023","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1710163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:40:02Z","timestamp":1770964802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1710163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":58,"alternative-id":["10.3389\/falgy.2026.1710163"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1710163","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1710163"}}